Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: COVID-2019 therapeutics - Green Cross LabCell/Kleo Pharmaceuticals

Drug Profile

Research programme: COVID-2019 therapeutics - Green Cross LabCell/Kleo Pharmaceuticals

Latest Information Update: 06 Apr 2020

At a glance

  • Originator Green Cross LabCell; Kleo Pharmaceuticals
  • Class Antivirals; Natural killer cell therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell replacements; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 31 Mar 2020 Kleo Pharmaceuticals and Green ross LabCell collaborate to co-develop therapies for COVID-2019 infections
  • 31 Mar 2020 Early research in COVID-2019 infections (Combination therapy) in South Korea (Parenteral)
  • 31 Mar 2020 Early research in COVID-2019 infections (Combination therapy) in USA (Parenteral)

Development Overview

Introduction

Kleo Pharmaceuticals and Green cross LabCell are developing combination therapy of Antibody Recruiting Molecule and (ARM™) and allogeneic natural killer cells, for the treatment of COVID-2019 infections. Under the collaboration, Kleo will leverage its proprietary ARM platform whereas green cross Labcell willlaverage its allogeneic, or “off-the-shelf” natural killer cell therapies platform. Antibody recruiting molecule (ARM™) are bispecific molecules, designed to recruit the endogenous antibodies on virus particles, targeting them for destruction by engaging natural killer (NK) cells. It works as a bridge by enabling coating of antibodies to the cell and leading to the destruction of the virus particle through innate antibody-mediated immune mechanisms. Early research is underway in South Korea and the US.

ARMs are bifunctional molecules composed of two active terminus connected by a linker. One of the terminus binds tightly to a target molecule on SARS-Cov-2 virus. The other universal antibody binding terminus (uABT) binds to all endogenous antibodies independent of their antigen binding specificity. As a result, the target virus particle is "opsonised" by antibodies which then bring the allogeneic natural killer cells to eliminate the virus through various antibody-dependent destruction mechanisms. Moreover, the ARMs can produce a long-term vaccination effect by activating and expanding immune memory cells.

Company Agreements

In March 2020, Kleo Pharmaceuticals entered into a research collaboration with Green Cross LabCell to discover and develop therapies for the treatment of COVID-2019 infections. Under the collaboration, Kleo will leverage its ARM technology platform to develop fully synthetic bifunctional molecules and Green Cross LabCell will leverage its allogeneic natural killer cell therapy platform, to develop a combination therapy for COVID-2019 infections. [1]

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Antivirals, Natural killer cell therapies
  • Target Natural killer cell
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell replacements; Natural killer cell stimulants
  • WHO ATC code

    J05 (Antivirals for Systemic Use)

    V03A-X (Other therapeutic products)

  • EPhMRA code

    J5 (Antivirals for Systemic Use)

    V3X (All Other Therapeutic Products)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Combination therapy Research South Korea, USA Parenteral / unspecified Green Cross LabCell, Kleo Pharmaceuticals 31 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Kleo Pharmaceuticals Originator USA
Green Cross LabCell Originator South-Korea
Kleo Pharmaceuticals Owner USA
Green Cross LabCell Owner South-Korea

Development History

Event Date Update Type Comment
31 Mar 2020 Licensing Status Kleo Pharmaceuticals and Green ross LabCell collaborate to co-develop therapies for COVID-2019 infections [1] Updated 06 Apr 2020
31 Mar 2020 Phase Change Early research in COVID-2019 infections (Combination therapy) in South Korea (Parenteral) [1] Updated 06 Apr 2020
31 Mar 2020 Phase Change Early research in COVID-2019 infections (Combination therapy) in USA (Parenteral) [1] Updated 06 Apr 2020

References

  1. Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC) To Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy.

    Media Release
Back to top